Although overall survival (OS) has greatly improved in recent years for patients with multiple myeloma, there are variations and growing disparity for patients of minority race or ethnicity, according to an analysis from the Surveillance, Epidemiology, and End Results (SEER) program. Dianne Pulte, MD, of Thomas Jefferson University in Philadelphia, PA, presented the findings at the 2011 annual meeting of the American Society of Hematology.
San Diego, CA—The value of maintenance therapy in patients with newly diagnosed multiple myeloma who are not eligible for stem-cell transplant (such as the elderly) is still debated. Studies presented at the American Society of Hematology 2011 annual meeting showed that maintenance therapy can delay disease progression, although an overall survival (OS) advantage is not yet evident.
Lenalidomide Maintenance Doubles PFS
Results 1 - 6 of 6